Attorney Docket No: GRFN-020/01US

Examiner: Not yet assigned

Art Unit: 1615

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on January 27, 1999.

ŦECH CENTER 1600/2**980** 

# IN THE UNITED STAGES FAXENT AND TRADEMARK OFFICE

AUG 1 5 2000

In re application of

Siani et al.

Serial No:

09/144,838

Filed:

August 31, 1998

For:

MODULAR PROTEIN LIBRARIES AND METHODS OF PREPARATION

**Assistant Commissioner for Patents** Washington, D.C. 20231



#### TRANSMITTAL OF REFERENCES

Transmitted herewith are the following documents:

- 1. A copy of an Information Disclosure Statement Transmittal previously submitted on December 4, 1998
- 2. A copy of an Information Disclosure Statement and PTO form 1449 previously submitted on December 4, 1998
- 3. References Nos. [F1, ID][=D3, D5, D6, D8, ID9, D111, D12, D14, D16=D31, 1D33-D36, D38-D45, D50-D56, D59, and D60 cited on PTO form 1449, not previously submitted! These references are being submitted under separate cover as stated on the enclosed copy of the Information Disclosure Statement.
- 4. Fee Transmittal
- 5. Return Receipt Postcard, postage prepaid

The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 03-3117:

[X] Any national application filing fees under 37 CFR 1.16.

AUG 1620000

[X] Any patent application processing fees under 37 CFR 1.17.

TECH CENTER 1600/2900

Cooley Godward LLP Five Palo Alto Square 3000 El Camino Real Palo Alto, CA 94306 Attn: Patent Group Ph. (650) 843-5000 Fx. (650) 857-0663

JAB:BJW

Respectfully submitted,

COOLEY GODWARD LLP

James A. Bradburne, Ph.D.

Reg. No. 38,389

Attorney Docket No: GRFN-020/01US

AUG 1 5 2000 Express Mail Label Number: EM100149058U

**PATENT** 

Date of Deposit:

December 4, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Sequence, Washington, D.C. 20231.

Elaine Calimquim

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Michael A. Siani, et al.

Serial No.:

09/144,838

Examiner:

Not yet assigned

Filed:

August 31, 1998

Art Unit:

1615

For:

MODULAR PROTEIN LIBRARIES AND METHODS OF PREPARATION

Assistant Commissioner for Patents Washington, D.C. 20231

#### INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

- Transmitted herewith is: 1.
  - Fee Transmittal X
  - Information Disclosure Statement
  - PTO Form 1449

- Copies of references listed on the PTO form 1449: [X]
  - Copies of all listed references are enclosed. Π
  - Copies of the following listed references are enclosed: F2-F9, D4, D7, D10, D13, D15, D32, D37, D44, D46-D49, D57, and D58.
  - Copies of the following listed references are not enclosed and will be [X]submitted under separate cover: F1, D1-D3, D5-D6, D8-D9, D11-D12, D14, D16-D31, D33-D36, D38-D43, D45, D50-D56, and D59-D60;

	[X]	Return	n Postcard Receipt, postage prepaid.		
	0	Englis	th translation of foreign language reference(s)		
	0		No copies of references listed on the PTO Form 1449 are being provided as this application claims continuation status to application Serial No. and copies of the listed references were provided in the parent application.		
	0	Сору	of foreign examination report		
		0	English translation of foreign examination report		
2.	[X]	This I	nformation Disclosure Statement is filed before the later of:		
		0	three months from the filing date of this national application;		
		0	three months from the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or		
		[X]	the mailing date of a first office action on the merits.		
	In acc	ordance	e with 37 CFR 1.97(b), no fee is required.		
3.	0		nformation Disclosure Statement is filed after the events noted in paragraph before either:		
			Final action under 37 CFR 1.113, or		
	•	0	Notice of Allowance under 37 CFR 1.311.		
	In acc	ordance	e with 37 CFR 1.97(c) also enclosed is:		
			Fee under 37 CFR 1.17(p) in the amount of \$240.00; or		
		0	Statement as stated below.		
4.	0	This Information Disclosure Statement is filed before the payment of the issue fee, but after either:			
,			Final action under 37 CFR 1.113, or		
		0	Notice of Allowance under 37 CFR 1.311.		
	In acc	ordance	e with 37 CFR 1.97(d) also enclosed is:		
		0	Statement as specified in 37 CFR 1.97(e)		

શુ ૅ	,		Petition requesting consideration of the Information Disclosure Statement; and				
)			The petition fee set forth in 37 CFR 1.17(i) in the amount of \$240.00.				
5.	Statement. The undersigned states:						
	0	•	Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or				
	0		No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.				
6.	Fees						
		Check	in the amount of \$0.00 is attached.				
	0	Please	charge Deposit Account No. 03-3117 in the amount of \$0.00.				
	[X]	No fee	e is required.				
	[X]		The Commissioner is hereby authorized to charge any underpayment of credit any overpayment of the following fees associated with this communication to Deposit Account No. 03-3117:				
	•		[X] Any patent application processing fees under 37 CFR 1.17.				

Cooley Godward LLP
Attn: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155

Tel: (650) 843-5000 Fax: (650) 857-0663

JAB:BJW

Respectfully submitted, COOLEY GODWARD LLP

By:

James A. Bradburne, Ph.D.

Reg. No. 38,389



Attorney Docket No: GRFN-020/01U

AUG 1 5 2000

PATENT

Express Mail Label Number:

Date of Deposit:

**December 4, 1998** 

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Sequence, Washington, D.C. 20231.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Michael A. Siani, et al.

Examiner:

Not yet assigned

Serial No.:

09/144,838

Art Unit:

1615

Filed:

August 31, 1998

For:

MODULAR PROTEIN LIBRARIES AND METHODS OF PREPARATION

Assistant Commissioner for Patents Washington, D.C. 20231

#### INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits this Information Disclosure Statement in accordance with 37 CFR 1.98 and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.

Applicant makes no representation that a search has been conducted by the Applicant, or that there is not possibly more relevant art. Applicant also makes no representation that the information submitted herewith is in fact material.

No copies enclosed: The references listed on the enclosed Form PTO П 1449 have been previously cited by or submitted to the PTO as recited in the Information Disclosure Statement Transmittal that accompanies this paper. In accordance with the provisions of 37 C.F.R. 1.98(d), no copies of these references are being provided.





- Copies enclosed: Copies of the following references listed on the [X]enclosed Form PTO 1449 are being provided with this Information Disclosure Statement: F2-F9, D4, D7, D10, D13, D15, D32, D37, D44, D46-D49, D57, and D58.
- Copies not enclosed: Copies of the following references listed on the [X]. enclosed Form 1449 are not being provided with this Information Disclosure Statement, copies of these references will be forwarded under separate cover: F1, D1-D3, D5-D6, D8-D9, D11-D12, D14, D16-D31, D33-D36, D38-D43, D45, D50-D56, and D59-D60.
- The enclosed references were cited in a foreign examination report in a related case. A copy of the search report and the cited references are attached hereto.
  - The search report is not in the English language and a translation of the search report is enclosed.
- At least one of the enclosed references is not in the English language. П
  - English translation(s) are enclosed. П
  - Enclosed is an explanation of the relevance of non-English  $\Pi$ references for which an English translation is not available.
    - The explanation is in the form of an English language search report.

The subject application is believed patentable over any of the above references.

Cooley Godward LLP

Attn: Patent Group Five Palo Alto Square 3000 El Camino Real

Palo Alto, CA 94306-2155

Tel: (650) 843-5000

Fax: (650) 857-0663

Respectfully submitted, COOLEY GODWARD LLP

By:

James A. Bradburne. Ph.D.

Reg. No. 38,389

JAB:

Enclosures:

1. Form PTO 1449

2. Copies of the following listed references F2-F9, D4, D7, D10, D13, D15, D32,

D37, D44, D46-49, D57, and D58 cited on Form PTO-1449

XAMINER NITIAL	<u>}</u> (	(Use several she			APPLICANT: Michael A.				
NITIAL	<u>}</u> (	OPY		<b>,</b>					
NITIAL	)(   	OPY				ciani at	<b>-1</b>		
NITIAL					FILING DAT		GROU	ng C	
NITIAL					August 31,	1998	1615	<del>,</del>	
NITIAL				U.S. PATENT DOCT		T			
1	-	DOCUMENT NUMBER	DATE	NAI	MB	CLASS	SUBCLASS	FILING D	ATE
- 1	P1				<del></del>			•	
	1			1					
			FC	REIGN PATENT DO	CUMENTS		<u> </u>		
								TRANSLA	LION
.		DOCUMENT NUMBER	DATE	COUN	FTRY	CLASS	SUBCLASS	YES	N
	?1	BP 0,156,588	02.10.85	Europe					1
1						IPE			
F	72	EP 0,503,683	16.09.92	Europe		١	<b>{</b> `		
				International		1 5 2000			+
ľ	?3	WO 93/20098	14.10.93	International	- L				
	74	WO 95/00846	05.01.95	International	1	PADEMARY			十
					,				
. 1	?5	WO 95/04543	16.02.95	International	1				
						ļ	<u> </u>		_
I	76	WO 95/34641	21.12.95	International	1		1		
					•				+
] [	?7	WO 96/34878	07.11.96	International	1				
	78	WO 94/01102	20.01.94	Internationa	1	<del></del>	<u> </u>		$\dashv$
]*		W 747 02202							
	<b>F</b> 9	WO 98/28434	02.07.98	Internationa	1				
1									
				ing Author, Tit					
1	01	Beall et al., "two regions of	Site-directe	d mutagenesis o	for biolog	chemoattra	ctant prot	ein-l ider chemistry	1tif: (19
1		two regions of 313:633-640	cue borabeh	crde essencigi	. Tot protod				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Bleul et al. , \* The lymphocts chemoattractant SDF-1 is a ligand for LBSTR/fusion and blocks HIV-1 entry, \* Nature (1996) 382:829

Boshoff et al., \*Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines,\* Science (1997) 278:290-294

DATE CONSIDERED



		II S DEPARTMENT OF COLOR	700777					
(REV. 8-83)	,	U.S. DEPARTMENT OF COMM PATENT AND TRADEMARK OF		SERIAL NO. 09/144,838				
(1021. 5 55.				10,211,030				
	INFORMATION DISCLOS (Use several sheets							
•	/036 36/6181 3mccc3	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	APPLICANT:					
	~ ~ ~ ~ ~ ~	cont in	Michael A. Siani, et al.					
$\sim$	$\mathcal{M}$	AUG 15 ZUUU E	FILING DATE	GROUP				
لحال		AUG 1 5 2000 35	August 31, 1998	1615				
		TENT & TO AD SMIRET						
	OTHER PUBLICATION	S (including Author, Tit	le, Date, Pertinent P	Pages, Stc.)				
DS	Brenner et al., "Encoded combinatorial chemistry," Proc. Natl. Acad. Sci. U.S.A. (1992) 89:5381-5383							
D6	Bunin et al., "The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library," Proc. Natl. Acad. Sci. USA (1993) 91:4708-4712							
D7	Campell et al., "Chemokines and the arrest of lymphocytes rolling under flow conditions," Science (1998) 279:381-384							
D8	Canne et al., "Total chemical synthesis of a unique transcription factor-related protein - CMYC-MAX," J. Am. Chem. Soc (1995) 117:2998-3007							
D9	Canne et al., "A general method for the synthesis of thioester resin linkers for use in the solid phase synthesis of peptide-alpha-thioacids," Tetrahedron Lett. (1995) 36:1217-1220							
D10	Canne et al., "Solid phase protein synthesis by chemical ligation of unprotected peptide segments in aqueous solution," Poster #147, pp.1-6, The 1997 American Peptide Symposium, Nashville, Tennessee, U.S.A., June 14-19, 1997							
D11	Carrasco et al., "Direct monitoring of organic reactions on polymeric supports," Tetrahedron Letters (1997) $38:6331-6334$							
D12	Clark-Lewis et al. design of analogs a	, "Structural requirement CXC chemokine hybrids	ents for interleuki , J. Biol. Chem. (19	n-8 function identified by 994) 269:16075-16081				
D13	Cohen, "Exploiting the HIV-Chemokine Nexus," Science (1997) 275:1261-1264							
D14	Cwirla et al., "Per Proc. Natl. Acad. S	ptides on phage: a vast ci. USA (1990) 87:6378-6	library of peptide 382	s for identifying ligands,				
D15	Dawson et al., "Synthesis of proteins by native chemical ligation," Science (1994) 266:776-779							
D16		dom peptide libraries: ( 404-406	source of specific	protein binding molecules,				
D17	DeWitt et al., "Div	rersomers: an approach to: U.S.A. (1993) 90:690	o nonpeptide, nonoli 9-6913	gomeric chemical diversity,				
	ı		IDATE CONSTDERED					

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED



Form 210-144			SERIAL NO.			
(REV. 8-83)	patent and trademark of	GRFN-020/01	09/144,838			
	INFORMATION DISCLOSURE STATEMENT PE					
		APPLICANT: Michael A. Siani, et al.				
		FILING DATE August 31, 1998	GROUP 1615			
<del>, , , , , , , , , , , , , , , , , , , </del>	TRADEMARK OF					
	OTHER PUBLICATIONS (including Author, Tit	le, Date, Pertinent Pages,	Btc.)			
D18	ments of distances in					
D19	Fairclough and Cantor, "The use of singlet-singlet energy transfer to study macromolecular assemblies," Meth. Enzymol. (1978) 48:347-379					
D20	Purka et al., Abstr. 14th Int. Congr. Biochem., Prague, Czechoslovakia, Vol 5, pg 47. Abstr. 10th Intl. Symp. Med. Chem., Budapest, Hungary, (1988), pg 288					
D21	rtner et al., "Site-specific religation of G-CSF fragments through a thioester bond," conj. Chem. (1994) 5(4):333-338					
D22	Gallop et al., "Applications of combinatorial technologies to drug discovery, 1," J. Med. Chem. (1994) 37:1233-1251					
D23	Gauthier et al., "A new sensitive fluorogen the cystatin inhibitory site," Arch. Bioche	hier et al., "A new sensitive fluorogenic substrate for paper based on the sequence of cystatin inhibitory site," Arch. Biochem. Biophys. (1993) 306:304-308				
D24	Geahlen et al., "A general method for prepterminus," Anal. Biochem. (1992) 202:68-70	aration of peptides biotic	nylated at the carboxy			
D25	Geysen et al., "Use of peptide synthesi resolution of a single amino acid," Proc. N	s to probe viral antiger at. Acad. Sci. U.S.A. (198	ns for epitopes to a 4), 81:3998-4002			
D26	Gordon et al., "Applications of combinatorial technologies to drug discovery, 2," J. Med. Chem. (1994) 37:1385-1401					
D27	Houghten et al., " General method for the rapid solid-phase synthesis of large number of peptides," Proc. Natl. Acad. Sci. U.S.A. (1985) 82:5131-35					
D28	Houghten et al., "Generation and use of syr research and drug discovery," Nature (1991)	nthetic peptide combinatori 354:84-86	al libraries for basic			
D29	Hromas et al., *Cloning and characterization of exodus, a novel beta-chemokine, * Blood (1997) 89(9):3315-3322					
D30	Lu et al., "Probing intermolecular main che inhibitor complexes," Biochemistry (1997)	et al., "Probing intermolecular main chain hydrogen bonding in serine proteinase-protein ibitor complexes," Biochemistry (1997) 36(4): 673-679				
D31	Maggiora et al.; "A general method for the protease substrates using solid-phase pepti	e preparation of internall de synthesis," J Med. Chem	y quenched fluorogenic . (1992) 35:3727-3730			
. D32	Moore et al., "Molecular mimicry of human KSHV," Science (1996) 274:1739-1744	cytokine an cytokine res	ponse pathway genes by			
D3:	Moos et al., "Recent advances in the gener Medicinal Chemistry (1993) 28:315-324	ation of molecular diversi	ty," Annual Reports in			
D34	Muir and Kent, "The chemical synthesis	of proteins," Curr. Opin	. Biotechnology (1993)			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw lir through citation if not in conformation and not considered. Include a copy of this form with the next communication applicant.



DATE CONSIDERED

		U.S. DEPARTMENT OF COMM	ATTY. DOCKET_	SERIAL NO.			
Form PT (REV. 8		PATENT AND TRADEMARK OF		09/144,838			
		INFORMATION DISCLOSURE STATEMENTS (Use several sheets if noted any)					
			APPLICANT: Michael A. Siani, et a	1.			
1	0	AUG 1 5 2000 (5)	FILING DATE August 31, 1998	GROUP 1615			
	(A)	THE PROPERTY OF					
		OTHER PUBLICATIONS (including Author, Tit.	le, Date, Pertinent Page	es, Stc.)			
٠	D35	Needels et al., "Generation and screening library," Proc. Natl. Acad. Sci. USA (1993)	of an oligonucleotide-e 90:10700-10704	encoded synthetic peptide			
	naling characteristics of						
			nding proteins selected from combinatorial libraries of an alpha-helical or domain, Nature Biotechnology (1997) 15:772-777				
	D38	Oberlin et al., "The CXC chemokine SDF-1 infection by T-cell-line-adapted HIV-1," No.	is the ligand for Lature (1996) 382:833-83	ESTR/fusion and prevents			
	D39	Oppenheim, "Overview of chemokines," Adv.	Exp. Med. Biol. (1993) .	351:183-186			
-		Pavia et al., "The generation of moleculatt. (1993) 3:387-396	lar diversity," Bicorga	nic and Medicinal Chem.			
	D41	Peled et al., "Synthetic S-2 and H-5 structure, membrane interaction, and assem (1994) 33:7211-7219	segments of the Shake bly within phospholipid	r K* channel: secondary membranes, ** Biochemistry			
	D42	Proudfoot et al., "Extension of recomb initiating methionine produces a potent an	inant human RANTES b tagonist, J.B.C. (1996	y the retention of the 271:2599-2603			
	D43	Rajarathnam et al., "Neutrophil activat: 264:90-92	on by monomeric inter	cleukin-8,"Science (1994)			
	D44	Schnölzer et al., "In situ neutralization Int. J. Peptide Protein Res. (1992) 40:180	in Boc-chemistry solid -193	phase peptide synthesis,"			
	D45	Schnölzer and Kent, "Constructing proteins backbone-engineered HIV protease," Science	by dovetailing unprote (1992) 256:221-225	ected synthetic peptides:			
	D46	Siani et al., "Rapid modular synthesis of International Business Communications 3rd San Francisco, CA, U.S.A., September 30-Oc	Annual International (	gues," Poster, pp. 1-13, Conference on Chemokines,			
	D47	Siani, et al., "Rapid modular total che sequence data," Poster #360, pp. 1-6, 1 Tennessee, U.S.A., June 14-17,1997	mical synthesis of ch The 15 <sup>th</sup> American Pepti	emokines based on genome de Symposium, Nashville,			
	D48	pp. 1-12, NMHCC, Chemokines and Host-Cel U.S.A., January 1997	l Interaction Conferen	ice, Baltimore, Maryland,			
	D49	Simmons et al., "Potent inhibition of HIV a novel CCR5 antagonist," Science (1997) 2	-1 infectivity in macro 76:276-279	phages and lymphocytes by			
	D50	Smith G.P., "Filamentous fusion phage: antigens on the virion surface," Science	novel expression vect 1985) 228:1315-1317	ors that display cloned			

DATE CONSIDERED



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form PTO-1449	U.S. DEPARTMENT OF COMM	ATTY DOCKET	SERIAL NO.				
(REV: 8-83)	PATENT AND TRADEMARK OF		09/144,838				
	INFORMATION DISCLOSURE STATEMENT	•					
	(Use several sheets if netestable)	i					
	01118	APPLICANT:					
6		Michael A. Siani, et al. FILING DATE GROUP					
((	AUG 1 5 2000 %)	FILING DATE August 31, 1998	1615				
	THE TRADERANKEE						
	OTHER PUBLICATIONS (including Author, Tit.	le, Date, Pertinent Pages,	Btc.)				
D51	Sticht et al., "Structure and activity stimulatory-activity protein," Eur. J. Biod	of a chimeric interleuk chem. (1996) 235:26-35	in-8-melanoma-growth-				
D52	Strahilevitz et al., "Spectrum of antimicrits precursor form in phospholipid membrane	es," Biochemistry (1994) 33	:10951-10960				
D53	Tam et al., "Peptide synthesis / using un methods," Proc. Natl. Acad. Sci. USA (1995	) 92:12485-12489					
	Ueda et al., "Chemically synthesized SDF- agent for CXCR4/Fusion/LESTR-expressing 272:24966-24970	human leukocytes, J.	Biol. Chem. (1997)				
D55	Wernette-Hammond et al., "Receptor recognition and specificity of interleukin-8 is determined by residues that cluster near a surface-accessible hydrophobic pocket," $J$ . Biol. Chem. (1996) 271:8228-8235						
	Wilken et al., "Solid Phase Chemical Ligation-A Paradigm for Post Genomic Pharmaceuticals," Fifth International Symposium on Solid Phase Synthesis and Combinatorial Chemical Libraries, London, England, U.K., (September 4, 1997)						
D57	Wilken and Kent, "Chemical protein synthesis," Curr. Opin. Biotech. (1998) 9:412-426						
	Wu et al., "Resonance energy transfer: (1994) 218:1-13						
		itl. Acad. Sci. USA (1998)	75:9184-9189				
D60	Zuckermann et al., "Discovery of nanomol receptors from a diverse N-(substituted) 37:2678-2685	ar ligands for 7-tranmembr glycine peptoid library, "	rane G-protein-coupled 7. Med. Chem. (1994),				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication tapplicant.

DATE CONSIDERED

COPY